J Stroke.  2024 Jan;26(1):121-124. 10.5853/jos.2023.02250.

Adding Tirofiban on Top of Recombinant Tissue Plasminogen Activator May Improve Clinical Outcome in Acute Stroke Patients

• Liu R
• Liang Z
• Li W
• Zhan Y
• Xu L
• Yang S
• Zheng G
• Jiang L
• Xie L
• Sun Z
• Hu Y

• KMID: 2551356
• DOI: http://doi.org/10.5853/jos.2023.02250

Figure

• 

  Figure 1. Modified Rankin Scale (mRS) scores at 90 days after treatment. After 90 days, the rate of prognostic improvement (mRS 0–2) in the recombinant tissue plasminogen activator with tirofiban (rt-PA+T) group was increased compared with the recombinant tissue plasminogen activator (rt-PA) group (76.1% vs. 63.6%, P=0.042).

Reference

References

1. Wang YJ, Li ZX, Gu HQ, Zhai Y, Zhou Q, Jiang Y, et al. China Stroke Statistics: an update on the 2019 report from the National Center for Healthcare Quality Management in Neurological Diseases, China National Clinical Research Center for Neurological Diseases, the Chinese Stroke Association, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke Collaborations. Stroke Vasc Neurol. 2022; 7:415–450.

2. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019; 50:e344–e418.

3. Abumiya T, Fitridge R, Mazur C, Copeland BR, Koziol JA, Tschopp JF, et al. Integrin alpha(IIb)beta(3) inhibitor preserves microvascular patency in experimental acute focal cerebral ischemia. Stroke. 2000; 31:1402–1409.

4. Li W, Lin L, Zhang M, Wu Y, Liu C, Li X, et al. Safety and preliminary efficacy of early tirofiban treatment after alteplase in acute ischemic stroke patients. Stroke. 2016; 47:2649–2651.

5. Liang Z, Zhang J, Huang S, Yang S, Xu L, Xiang W, et al. Safety and efficacy of low-dose rt-PA with tirofiban to treat acute non-cardiogenic stroke: a single-center randomized controlled study. BMC Neurol. 2022; 22:280.

6. Dong Y, Han Y, Shen H, Wang Y, Ma F, Li H, et al. Who may benefit from lower dosages of intravenous tissue plasminogen activator? Results from a cluster data analysis. Stroke Vasc Neurol. 2020; 5:348–352.

7. Koga M, Toyoda K, Kimura K, Yamamoto H, Sasaki M, Hamasaki T, et al. THrombolysis for Acute Wake-up and unclear-onset Strokes with alteplase at 0·6 mg/kg (THAWS) Trial. Int J Stroke. 2014; 9:1117–1124.

8. Rubiera M, Alvarez-Sabín J, Ribo M, Montaner J, Santamarina E, Arenillas JF, et al. Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke. Stroke. 2005; 36:1452–1456.

9. Wu C, Sun C, Wang L, Lian Y, Xie N, Huang S, et al. Low-dose tirofiban treatment improves neurological deterioration outcome after intravenous thrombolysis. Stroke. 2019; 50:3481–3487.

10. Khatri P, Conaway MR, Johnston KC; Acute Stroke Accurate Prediction Study (ASAP) Investigators. Ninety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic stroke. Stroke. 2012; 43:560–562.